Novo Nordisk A/S (NYSE:NVO) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Tuesday. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11, FiscalAI reports. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.

Novo Nordisk A/S Stock Down 4.5%

NYSE NVO traded down $2.25 on Wednesday, hitting $48.05. The stock had a trading volume of 21,000,244 shares, compared to its average volume of 23,893,857. The business’s fifty day moving average price is $53.78 and its 200 day moving average price is $54.18. The stock has a market cap of $214.53 billion, a price-to-earnings ratio of 13.95 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares during the last quarter. AQR Capital Management LLC boosted its stake in Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC grew its position in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the last quarter. Invesco Ltd. grew its position in Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after purchasing an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new position in Novo Nordisk A/S during the 2nd quarter valued at approximately $314,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on NVO shares. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. Jefferies Financial Group initiated coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating on the stock. HSBC restated a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, CICC Research initiated coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $57.79.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema (next‑generation diabetes/obesity candidate) delivered strong late‑stage results vs. semaglutide — superior HbA1c and meaningful weight loss, supporting long‑term pipeline value. Read More.
• Positive Sentiment: Q4/2025 earnings beat consensus on EPS and revenue, indicating underlying demand even as guidance disappointed. Read More.
• Positive Sentiment: Novo launched a 2026 share‑buyback programme (overall up to DKK 15bn; immediate programme up to DKK 3.8bn) which supports capital return and offsets dilution from incentive plans. Read More.
• Neutral Sentiment: Management changes: Jamey Millar named head of U.S. business and Hong Chow head of product & portfolio strategy — operational moves that could matter for U.S. execution. Read More.
• Negative Sentiment: Guidance shock: Novo forecast adjusted sales and operating profit declines of roughly 5%–13% in 2026 (constant FX), citing lower realized prices, U.S. price cuts and loss of exclusivity — the primary driver of today’s selloff. Read More.
• Negative Sentiment: CEO warnings and pricing pressure: Management described U.S. Wegovy price reductions as “painful” and warned investors that performance may get worse before improving, signaling sustained margin and topline pressure. Read More.
• Negative Sentiment: Competitive risk rising: Pfizer reported monthly GLP‑1 data (Metsera) with weight‑loss outcomes comparable to peers, intensifying pricing and market‑share competition in obesity medicines. Read More.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.